Previous Close | 32.97 |
Open | 33.24 |
Bid | 33.20 x 1100 |
Ask | 33.50 x 800 |
Day's Range | 32.60 - 33.76 |
52 Week Range | 26.81 - 56.25 |
Volume | |
Avg. Volume | 1,016,411 |
Market Cap | 3.788B |
Beta (5Y Monthly) | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.08 |
Earnings Date | Feb 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 65.38 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARWR
PASADENA, Calif., January 25, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Arrowhead...
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT On January 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced topline results for the Phase 2 SEQUOIA trial of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD) liver disease. A copy of the slides discussing the results can be found here . The SEQUOIA trial is a placebo